Abstract
Summary
The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.
“The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market”
Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.
“infectious disease segment accounted for the largest share of the disease type segment in 2022.”
Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.
“Asia Pacific region is likely to grow at a faster pace.”
The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side - 20%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
• Dynavax Technologies (US)
• Croda International plc (UK)
• GSK plc (UK)
• Seppic (France)
• Novavax (US)
• SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
• Agenus Inc. (US)
• Phibro Animal Health Corporation (US)
• Aurorium (Vertellus) (US)
• Merck KGaA (Germany)
• Vaxine Pty Ltd. (Australia)
• Hawaii Biotech Inc. (US)
• CSL Limited (Australia)
• OZ Biosciences (US)
• InvivoGen (US)
• Allergy Therapeutics (UK)
• EuBiologics Co., Ltd. (South Korea)
• Pacific GeneTech Limited (US)
• Riboxx GmbH (Germany)
• CaPtivate Pharmaceuticals LLC (US)
• Creative Diagnostics (US)
• LiteVax BV (Netherlands)
• Mukta Industries (India)
• Oncovir, Inc. (US)
• TiterMax USA, Inc. (US).
Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccine adjuvants market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.
Table of Contents
1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS & EXCLUSIONS 23
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED 24
1.3.3 CURRENCY CONSIDERED 24
1.4 RESEARCH LIMITATIONS 24
1.5 STAKEHOLDERS 25
1.6 SUMMARY OF CHANGES 25
1.7 RECESSION IMPACT 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH APPROACH 27
2.1.1 PRIMARY RESEARCH 28
2.1.2 SECONDARY DATA 29
2.2 MARKET SIZE ESTIMATION 30
2.2.1 INSIGHTS FROM PRIMARIES 32
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, ROUTE OF ADMINISTRATION, DISEASE TYPE, APPLICATION, TYPE, AND REGION) 33
2.3 GROWTH RATE ASSUMPTIONS 34
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.5 STUDY ASSUMPTIONS 36
2.6 RISK ANALYSIS 37
2.7 RECESSION IMPACT ANALYSIS 37
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 44
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 44
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2022) 45
4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2023 VS. 2028 46
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 49
- 5.2.1.1 Rising prevalence of infectious diseases 49
- 5.2.1.2 Increasing collaborations and partnerships among market players for adjuvanted vaccine development 50
- 5.2.1.3 Growing product pipeline 50
- 5.2.1.4 Growing focus on immunization programs 51
5.2.2 RESTRAINTS 52
- 5.2.2.1 Side effects and toxicity of adjuvants 52
5.2.3 OPPORTUNITIES 52
- 5.2.3.1 Growing funding for vaccines and increasing infectious disease research activities 52
- 5.2.3.2 Development of plant-based vaccine adjuvants 53
5.2.4 CHALLENGES 54
- 5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants and shark fishing 54
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
5.4 PRICING ANALYSIS 55
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS 55
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 55
5.5 TECHNOLOGY ANALYSIS 56
5.6 VALUE CHAIN ANALYSIS 57
5.7 ECOSYSTEM ANALYSIS 58
5.8 KEY CONFERENCES & EVENTS IN 2023-2024 59
5.9 REGULATORY ANALYSIS 60
5.9.1 REGULATORY LANDSCAPE FOR VACCINE ADJUVANTS 60
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
5.10 PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF SUPPLIERS 66
5.10.4 BARGAINING POWER OF BUYERS 66
5.10.5 DEGREE OF COMPETITION 66
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 69
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
5.11.2 BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS 70
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 71
6.1 INTRODUCTION 72
6.2 ADJUVANT EMULSIONS 72
6.2.1 EXTENSIVE USE OF ADJUVANT EMULSIONS IN HUMAN VACCINES TO DRIVE GROWTH 72
6.3 PATHOGEN COMPONENTS 74
6.3.1 INCREASING NUMBER OF PROMINENT PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE GROWTH 74
6.4 SAPONIN-BASED ADJUVANTS 77
6.4.1 INCREASING USE OF SAPONIN-BASED ADJUVANTS TO SUPPORT MARKET GROWTH 77
6.5 PARTICULATE ADJUVANTS 79
6.5.1 GROWING DEMAND FOR MINERAL-BASED ADJUVANTS TO BOOST MARKET 79
6.6 OTHER ADJUVANTS 82
7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 84
7.1 INTRODUCTION 85
7.2 INTRAMUSCULAR 85
7.2.1 BETTER ABSORPTION RATE ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION TO DRIVE MARKET GROWTH 85
7.3 SUBCUTANEOUS 88
7.3.1 FREQUENT USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET 88
7.4 OTHER ROUTES OF ADMINISTRATION 91
8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 93
8.1 INTRODUCTION 94
8.2 INFECTIOUS DISEASES 94
8.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 94
8.3 CANCER 97
8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 97
8.4 OTHER DISEASES 100
9 VACCINE ADJUVANTS MARKET, BY APPLICATION 102
9.1 INTRODUCTION 103
9.2 RESEARCH APPLICATIONS 103
9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 103
9.3 COMMERCIAL APPLICATIONS 106
9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 106
10 VACCINE ADJUVANTS MARKET, BY TYPE 109
10.1 INTRODUCTION 110
10.2 HUMAN VACCINE ADJUVANTS 110
10.2.1 INCREASING PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS TO AID MARKET GROWTH 110
10.3 VETERINARY VACCINE ADJUVANTS 113
10.3.1 INCREASING USE OF ADJUVANTED VACCINES AS PREVENTIVE CARE IN ANIMAL HEALTH TO DRIVE MARKET 113
11 VACCINE ADJUVANTS MARKET, BY REGION 116
11.1 INTRODUCTION 117
11.2 NORTH AMERICA 117
11.2.1 US 122
- 11.2.1.1 US to dominate North American market during forecast period 122
11.2.2 CANADA 125
- 11.2.2.1 Increasing government funding for vaccine research to drive market growth in Canada 125
11.2.3 NORTH AMERICA: RECESSION IMPACT 127
11.3 EUROPE 128
11.3.1 GERMANY 130
- 11.3.1.1 Increasing investments by various key players to drive market 130
11.3.2 UK 133
- 11.3.2.1 Rising investments in vaccine development to boost market growth 133
11.3.3 FRANCE 135
- 11.3.3.1 Growing focus on new vaccine development to drive market growth 135
11.3.4 ITALY 138
- 11.3.4.1 Growth in life science research to boost market 138
11.3.5 SPAIN 140
- 11.3.5.1 Increasing investments in vaccine development by government and private organizations to support market 140
11.3.6 REST OF EUROPE 142
11.3.7 EUROPE: RECESSION IMPACT 145
11.4 ASIA PACIFIC 145
11.4.1 CHINA 149
- 11.4.1.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 149
11.4.2 JAPAN 152
- 11.4.2.1 Government initiatives to boost market 152
11.4.3 INDIA 154
- 11.4.3.1 Growth of biotechnology sector to support market 154
11.4.4 REST OF ASIA PACIFIC 156
11.4.5 ASIA PACIFIC: RECESSION IMPACT 158
11.5 LATIN AMERICA 158
11.5.1 GROWING PHARMACEUTICAL & BIOTECHNOLOGY RESEARCH TO DRIVE MARKET GROWTH 158
11.5.2 LATIN AMERICA: RECESSION IMPACT 159
11.6 MIDDLE EAST & AFRICA 161
11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH 161
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 161
12 COMPETITIVE LANDSCAPE 164
12.1 INTRODUCTION 164
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 164
12.3 REVENUE SHARE ANALYSIS 165
12.4 MARKET SHARE ANALYSIS 165
12.5 COMPANY EVALUATION MATRIX 167
12.5.1 STARS 167
12.5.2 EMERGING LEADERS 167
12.5.3 PERVASIVE PLAYERS 167
12.5.4 PARTICIPANTS 168
12.5.5 COMPANY FOOTPRINT 169
- 12.5.5.1 Product footprint of top 25 companies 169
12.5.6 REGIONAL FOOTPRINT OF TOP 25 COMPANIES 170
12.6 START-UP/SME EVALUATION MATRIX 171
12.6.1 PROGRESSIVE COMPANIES 171
12.6.2 STARTING BLOCKS 171
12.6.3 RESPONSIVE COMPANIES 171
12.6.4 DYNAMIC COMPANIES 171
12.7 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 173
12.8 COMPETITIVE SCENARIO AND TRENDS 174
12.8.1 PRODUCT LAUNCHES & APPROVALS 174
12.8.2 DEALS 175
12.8.3 OTHER DEVELOPMENTS 176
13 COMPANY PROFILES 177
13.1 KEY MARKET PLAYERS 177
13.1.1 DYNAVAX TECHNOLOGIES 177
13.1.2 CRODA INTERNATIONAL PLC 182
13.1.3 GSK PLC 186
13.1.4 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP) 190
13.1.5 NOVAVAX 193
13.1.6 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 195
13.1.7 AGENUS INC 197
13.1.8 PHIBRO ANIMAL HEALTH CORPORATION 199
13.1.9 AURORIUM (FORMERLY VERTELLUS) 201
13.1.10 MERCK KGAA 203
13.1.11 VAXINE PTY LTD 206
13.1.12 HAWAII BIOTECH INC 207
13.1.13 CSL LIMITED 208
13.1.14 OZ BIOSCIENCES 211
13.1.15 INVIVOGEN 212
13.1.16 ALLERGY THERAPEUTICS 214
13.1.17 EUBIOLOGICS CO., LTD 216
13.1.18 PACIFIC GENETECH LIMITED 217
13.1.19 RIBOXX GMBH 218
13.1.20 CAPTIVATE PHARMACEUTICALS LLC 219
13.2 OTHER PLAYERS 220
13.2.1 CREATIVE DIAGNOSTICS 220
13.2.2 LITEVAX B.V 221
13.2.3 MUKTA INDUSTRIES 222
13.2.4 ONCOVIR, INC 223
13.2.5 TITERMAX USA, INC 223
14 APPENDIX 224
14.1 DISCUSSION GUIDE 224
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
14.3 CUSTOMIZATION OPTIONS 229
14.4 RELATED REPORTS 229
14.5 AUTHOR DETAILS 230